These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 23897419)

  • 1. Effect of venlafaxine and desvenlafaxine on drug efflux protein expression and biodistribution in vivo.
    Bachmeier C; Levin GM; Beaulieu-Abdelahad D; Reed J; Mullan M
    J Pharm Sci; 2013 Oct; 102(10):3838-43. PubMed ID: 23897419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine.
    Bachmeier CJ; Beaulieu-Abdelahad D; Ganey NJ; Mullan MJ; Levin GM
    Biopharm Drug Dispos; 2011 May; 32(4):233-44. PubMed ID: 21446053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients.
    Yamagata T; Kusuhara H; Morishita M; Takayama K; Benameur H; Sugiyama Y
    Drug Metab Dispos; 2007 Jul; 35(7):1142-8. PubMed ID: 17446265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.
    de Vries NA; Zhao J; Kroon E; Buckle T; Beijnen JH; van Tellingen O
    Clin Cancer Res; 2007 Nov; 13(21):6440-9. PubMed ID: 17975156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein.
    Lee YJ; Kusuhara H; Jonker JW; Schinkel AH; Sugiyama Y
    J Pharmacol Exp Ther; 2005 Jan; 312(1):44-52. PubMed ID: 15448171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions.
    Reyner EL; Sevidal S; West MA; Clouser-Roche A; Freiwald S; Fenner K; Ullah M; Lee CA; Smith BJ
    Drug Metab Dispos; 2013 Aug; 41(8):1575-83. PubMed ID: 23729661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of efflux transporters involved in distribution and disposition of apixaban.
    Zhang D; He K; Herbst JJ; Kolb J; Shou W; Wang L; Balimane PV; Han YH; Gan J; Frost CE; Humphreys WG
    Drug Metab Dispos; 2013 Apr; 41(4):827-35. PubMed ID: 23382458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of intestinal absorption of amtolmetin guacyl in rats: breast cancer resistant protein as a primary barrier of oral bioavailability.
    Rong Z; Xu Y; Zhang C; Xiang D; Li X; Liu D
    Life Sci; 2013 Feb; 92(3):245-51. PubMed ID: 23333829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
    Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.
    Chen Y; Agarwal S; Shaik NM; Chen C; Yang Z; Elmquist WF
    J Pharmacol Exp Ther; 2009 Sep; 330(3):956-63. PubMed ID: 19491323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of P-glycoprotein in intestinal transport versus the BBB transport of tetraphenylphosphonium.
    Swed A; Eyal S; Madar I; Zohar-Kontante H; Weiss L; Hoffman A
    Mol Pharm; 2009; 6(6):1883-90. PubMed ID: 19722701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo.
    Leggas M; Panetta JC; Zhuang Y; Schuetz JD; Johnston B; Bai F; Sorrentino B; Zhou S; Houghton PJ; Stewart CF
    Cancer Res; 2006 May; 66(9):4802-7. PubMed ID: 16651435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
    Dahan A; Amidon GL
    Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice.
    Zhang S; Wang X; Sagawa K; Morris ME
    Drug Metab Dispos; 2005 Mar; 33(3):341-8. PubMed ID: 15608138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
    Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.
    Lin F; Marchetti S; Pluim D; Iusuf D; Mazzanti R; Schellens JH; Beijnen JH; van Tellingen O
    Clin Cancer Res; 2013 Apr; 19(8):2084-95. PubMed ID: 23461902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of drug efflux transporter liabilities of darifenacin in cell culture models of the blood-brain and blood-ocular barriers.
    Miller DW; Hinton M; Chen F
    Neurourol Urodyn; 2011 Nov; 30(8):1633-8. PubMed ID: 21826715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo assessment of the impact of efflux transporter on oral drug absorption using portal vein-cannulated rats.
    Matsuda Y; Konno Y; Hashimoto T; Nagai M; Taguchi T; Satsukawa M; Yamashita S
    Drug Metab Dispos; 2013 Aug; 41(8):1514-21. PubMed ID: 23686319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of ABC transporters blood-brain barrier: the good, the bad, and the ugly.
    Miller DS
    Adv Cancer Res; 2015; 125():43-70. PubMed ID: 25640266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
    Graber-Maier A; Gutmann H; Drewe J
    Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.